As a leading research service provider pioneering advancements in the fields of oncology and immunotherapy, we stand at the forefront of innovation. Leveraging our ImmuBridge™ platform, we are committed to customizing multispecific antibodies to precisely meet the unique requirements of your cancer immunotherapy research.
Cutting-Edge Technology and Innovative Research
Extensive Expertise and Rich Experience
Next-generation Solutions for Tumor Immunotherapy
Utilizing the ImmuBridge™ platform, we are spearheading the development of a groundbreaking new cohort of T cell engager multispecific antibodies (MsAbs) meticulously crafted to target tumor antigens with unparalleled precision.
Our multispecific antibodies can be customized into precise carriers to deliver therapeutic agents directly to specific cancer cells, thereby reducing off-target effects.
Through the ImmuBridge™ platform, we create advanced TCEs that simultaneously activate multiple T cell targets, eliciting a potent immune response tailored to cancer cells.
Our ImmuBridge™ platform is specifically designed for developing multispecific antibodies targeting tumor antigens. We provide comprehensive research services for cancer immunotherapy to drive advancements in the field.
